Verrica Pharmaceuticals announced the first commercial sale of YCANTH to its exclusive distributor, FFF Enterprises. “We are pleased to announce the first commercial sale of YCANTH to our exclusive distribution partner FFF Enterprises,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. “As one of the nation’s most trusted specialty pharmaceutical distributors, FFF is well positioned to help Verrica introduce YCANTH(TM) as the first FDA-approved therapy for the treatment of molluscum contagiosum in the U.S. With this first commercial sale of YCANTH, we continue to execute our launch plans and we look forward to providing a more detailed update on our progress in November.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRCA:
- Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
- Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
- Verrica issues statement in support of FDA’s letters on treatment of MC
- Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
- Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results